akebia therapeutics inc
Akebia Therapeutics, Inc. Announces Resignation of Scott A. Canute as Class I Director
Jun 11 19
On June 10, 2019, Scott A. Canute, a Class I Director, notified Akebia Therapeutics, Inc. of his intention to resign from the company’s Board of Directors for personal reasons, effective as of June 10, 2019. The company and Mr. Canute entered into a consulting agreement, effective as of June 10, 2019, pursuant to which Mr. Canute will provide certain consulting services to the company.
Akebia Therapeutics, Inc. Launches AkebiaCares, an Enhanced Patient Access Program for People with Chronic Kidney Disease
Jun 11 19
Akebia Therapeutics, Inc. announced the launch of AkebiaCares, its enhanced patient access program. AkebiaCares provides patients, caregivers and health care providers with resources and important information to support greater access to Auryxia (ferric citrate). Auryxia is the only oral iron tablet approved in the U.S. to treat non-dialysis-dependent-chronic kidney disease (CKD) adult patients for iron deficiency anemia (IDA), and dialysis-dependent CKD adult patients for hyperphosphatemia. AkebiaCares offers services that include assisting patients and health care providers through the benefits investigation process, prior authorizations, appeals, copay assistance, and a patient assistance program for financially eligible patients. Patients can access these programs at www.akebiacares.com.
Akebia Therapeutics, Inc. Presents at Jefferies 2019 Healthcare Conference, Jun-04-2019 03:00 PM
May 29 19
Akebia Therapeutics, Inc. Presents at Jefferies 2019 Healthcare Conference, Jun-04-2019 03:00 PM. Venue: Grand Hyatt, 109 E 42nd St, New York, New York, United States. Speakers: John P. Butler, CEO, President & Director.
Akebia Therapeutics, Inc. Presents at Raymond James Life Sciences and MedTech Conference, Jun-19-2019 10:55 AM
May 29 19
Akebia Therapeutics, Inc. Presents at Raymond James Life Sciences and MedTech Conference, Jun-19-2019 10:55 AM. Venue: Lotte New York Palace hotel, New York, New York, United States. Speakers: John P. Butler, CEO, President & Director.
Akebia Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2019; Announces Full Enrollment of its Global Phase 3 INNO VATE Studies for Vadadustat
May 9 19
Akebia Therapeutics, Inc. reported unaudited consolidated earnings results for the first quarter ended March 31, 2019. For the quarter, the company reported collaboration revenue of $72,666,000 against $45,930,000 a year ago. Operating loss was $75,969,000 against $24,498,000 a year ago. Net loss was $72,421,000 against $23,418,000 a year ago. Net loss per basic and diluted share was $0.62 against $0.48 a year ago.
The company announced full enrollment of its global Phase 3 INNO VATE studies for vadadustat, that it has bolstered its commercial capabilities with the addition of Dell Faulkingham as Senior Vice President, Chief Commercial Officer, and appointed Steven K. Burke, M.D., as Senior Vice President, Chief Medical Officer. Dr. Burke will join the company from Proteon Therapeutics, Inc., where he has been Senior Vice President and Chief Medical Officer since 2006. The first quarter marked the achievement of another important milestone for Akebia with the announcement of positive top-line results from two Phase 3, active-controlled, pivotal studies evaluating vadadustat in Japanese patients with anemia due to chronic kidney disease (CKD), stated John P. Butler, President and Chief Executive Officer of Akebia Therapeutics. The company also announced the completion of enrollment in global Phase 3 INNO 2VATE studies evaluating vadadustat for the treatment of anemia due to CKD in dialysis-dependent CKD subjects. With the addition of Dell Faulkingham to executive team, and have strengthened the commercial capabilities and believe that well positioned to execute on revenue growth strategies for Auryxia.